Regulatory, Security Concerns Force Wuxi NextCODE To Cut China Ties

China Operations Face Potential Overhaul

As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study. 

US-China
US NATIONAL SECURITY CONCERNS AND CHINA REGULATIONS FORCE WUXI NEXTCODE TO CHOOSE SIDES • Source: Shutterstock

For many years, multinational firms have applied their successful recipes around the world, leveraging global scale and uniform practices. But now, growing nationalism and local-specific regulatory requirements may force them to change course.

In China, the government has turned increasingly tough about collecting and conducting research on genetic data from local patients, fearing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet